There are currently 669 clinical trials in Milwaukee, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical College of Wisconsin, Childrens Hospital of Wisconsin, Aurora Saint Luke's Medical Center and Aurora Sinai Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
NCT03266640
Recruiting
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Register for Updates
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
NCT03266653
Recruiting
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Register for Updates
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT03932786
Recruiting
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
Gender:
ALL
Ages:
All
Trial Updated:
11/12/2024
Locations: Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma
Register for Updates
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
NCT05200364
Recruiting
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Register for Updates
Long-term Follow-up Study of Patients Receiving CAR-T Cells
NCT03375619
Recruiting
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT0509... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/30/2024
Locations: Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
NCT04973137
Recruiting
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Light Chain (AL) Amyloidosis
Register for Updates
Clinical Decision Support Tool in PARDS Pilot Study
NCT04068012
Recruiting
Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS). This will be accomplished by using CDS t... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
10/28/2024
Locations: Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Ventilation Therapy; Complications, Ventilator-Induced Lung Injury, Ards
Register for Updates
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
NCT05766813
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/21/2024
Locations: Clinical Site, Milwaukee, Wisconsin
Conditions: Parkinson Disease
Register for Updates
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin +2 locations
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
Mechanisms of Fatigability With Diabetes
NCT04442451
Recruiting
Pre-diabetes (Pre-D) is a precursor to type 2 diabetes (T2D) and characterized by increased exercise fatigability of lower limb muscles, that can impede exercise performance. The cause for the increased fatigability in people with Pre-D is not known. Given the profound vascular disease present in people who have had uncontrolled diabetes for several years, we will determine whether dynamic, fatiguing contractions of the lower limb muscles in people with Pre-D are limited by vascular dysfunction... Read More
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
10/16/2024
Locations: Marquette University, Milwaukee, Wisconsin
Conditions: Pre-diabetes, Type 2 Diabetes
Register for Updates
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
10/09/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pediatric Pulmonary Hypertension
Register for Updates